FDA Clears Corbus' CRB-701 Registrational Study for HPV-Linked Oropharyngeal Cancer — Corbus Pharmaceuticals Holdings, Inc.

Event summary

FDA cleared Corbus' TEMPO-1 registrational study for CRB-701 in second-line oropharyngeal squamous cell carcinoma (OPSCC).
TEMPO-1 is a randomized controlled trial (n=250) comparing CRB-701 with investigator’s choice of capecitabine, cetuximab, or docetaxel.
CRB-701 achieved a 42.9% ORR in Phase 1/2 trials, with median DoR of 6.3 months and PFS of 5.6 months.
Corbus expects to initiate TEMPO-1 enrollment in September 2026.

The big picture

Corbus' FDA clearance for TEMPO-1 marks a critical step in addressing the unmet need for second-line OPSCC treatments, driven by increasing HPV-related cases. The study’s success could validate CRB-701 as a next-generation ADC, expanding Corbus’ oncology pipeline beyond its obesity-focused CRB-913 program.

What we're watching

Clinical Execution: Whether Corbus can maintain the 42.9% ORR observed in Phase 1/2 trials during TEMPO-1 enrollment.
Regulatory Pathway: The pace at which FDA accelerates approval based on ORR data, given CRB-701’s Fast Track designation.
Market Opportunity: How Corbus positions CRB-701 against existing treatments in a rising OPSCC patient population.